A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplant for Clostridium difficile Infection in Immunocompromised Patients

• Published in: Canadian journal of gastroenterology & hepatology Vol. 2018; no. 2018; pp. 1 - 10
• Main Authors: Donato, Anthony, Fadahunsi, Opeyemi, Jehangir, Asad, Victor, Samjeris, Poudel, Dilli Ram, Shogbesan, Oluwaseun, Shogbesan, Gbenga
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01-01-2018; Hindawi; Hindawi Limited
• Subjects: Antibiotics; Clostridium difficile - isolation & purification; Clostridium Infections - diagnosis; Clostridium Infections - microbiology; Clostridium Infections - therapy; Colonoscopy; Diarrhea; Fecal Microbiota Transplantation - methods; Feces; Feces - microbiology; Gastroenterology; HIV; Human immunodeficiency virus; Humans; Immunocompromised Host; Infections; Infectious diseases; Inflammatory bowel disease; Lymphoma; Microbiota; Mortality; Patients; Review; Studies; Systematic review; Transplants & implants; Treatment Outcome
• ISSN: 2291-2789; 2291-2797
• DOI: 10.1155/2018/1394379

Background. Fecal microbiota transplantation (FMT) has been shown to be effective in recurrent Clostridium difficile (CD) infection, with resolution in 80% to 90% of patients. However, immunosuppressed patients were often excluded from FMT trials, so safety and efficacy in this population are unknown. Methods. We searched MEDLINE and EMBASE for English language articles published on FMT for treatment of CD infection in immunocompromised patients (including patients on immunosuppressant medications, patients with human immunodeficiency virus (HIV), inherited or primary immunodeficiency syndromes, cancer undergoing chemotherapy, or organ transplant, including-bone marrow transplant) of all ages. We excluded inflammatory bowel disease patients that were not on immunosuppressant medications. Resolution and adverse event rates (including secondary infection, rehospitalization, and death) were calculated. Results. Forty-four studies were included, none of which were randomized designs. A total of 303 immunocompromised patients were studied. Mean patient age was 57.3 years. Immunosuppressant medication use was the reason for the immunocompromised state in the majority (77.2%), and 19.2% had greater than one immunocompromising condition. Seventy-six percent were given FMT via colonoscopy. Of the 234 patients with reported follow-up outcomes, 207/234 (87%) reported resolution after first treatment, with 93% noting success after multiple treatments. There were 2 reported deaths, 2 colectomies, 5 treatment-related infections, and 10 subsequent hospitalizations. Conclusion. We found evidence that supports the use of FMT for treatment of CD infection in immunocompromised patients, with similar rates of serious adverse events to immunocompetent patients.